EMA committee recommends Yuviwel (navepegritide) for children with achondroplasia

Aquesta entrada es mostra en anglès fins que se n'actualitzi la traducció.

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended authorising Yuviwel (navepegritide), a prodrug containing C-type natriuretic peptide, for children aged 2 years and older with genetically confirmed achondroplasia whose epiphyses (bone growth plates) are not closed. In a 52-week randomised, double-blind, placebo-controlled trial, it improved annualised growth velocity by 1.49 cm compared with placebo. The most common side effects were injection site reactions and hypertrichosis (abnormal hair growth). A CHMP opinion is followed by a European Commission decision.

Fonts

  1. 01Yuviwel: opinion on marketing authorisation(obre la font en una pestanya nova) European Medicines Agency
  2. 02Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026(obre la font en una pestanya nova) European Medicines Agency